Can you develop concise clinical practice points that translate community‑acquired pneumonia management recommendations into actionable bedside decisions, treatment protocols, and clinical algorithms?

Clinical Practice Points for Community-Acquired Pneumonia Management

Diagnostic Testing at Bedside

Do not routinely order urinary antigen tests for pneumococcus or Legionella in outpatients or non-severe CAP—reserve these tests exclusively for severe CAP or outbreak situations 1.

Actionable Testing Algorithm:

• Outpatient/Non-severe CAP: No urinary antigen testing needed; treat empirically
• Severe CAP (ICU admission, septic shock, or mechanical ventilation): Order both pneumococcal AND Legionella urinary antigens 1
• Legionella testing indicated if:
  • Severe CAP (any patient) 1
  • Recent travel history 1
  • Known outbreak association 1

Imaging Decisions:

Use lung ultrasound for CAP diagnosis when performed by experienced clinicians 2, 3. This provides point-of-care confirmation without radiation exposure and can guide immediate treatment decisions.

Viral Testing Interpretation:

During respiratory virus season, test for viruses, but do NOT withhold antibiotics based solely on positive viral results 4, 5. The critical caveat: viral detection in upper airways does not exclude bacterial co-infection, and withholding antibiotics puts patients at risk 5.

---

Site of Care Decision Protocol

Use validated severity scores (PSI or CURB-65) at initial presentation to determine admission versus outpatient treatment 1, 6, 4.

Immediate Triage Algorithm:

1. Outpatient treatment: No comorbidities, stable vitals, low severity score
2. Hospital admission: Comorbidities present, abnormal vitals, moderate severity
3. ICU admission: Severe CAP criteria (septic shock, mechanical ventilation needed, multi-organ failure)

Reassess patients periodically—severity can evolve rapidly 4.

---

Empiric Antibiotic Selection

Outpatient Treatment Protocol:

For healthy patients without comorbidities: Use amoxicillin 1g TID, doxycycline 100mg BID, or a macrolide ONLY if local pneumococcal resistance is <25% 1.

For patients with comorbidities (chronic heart/lung/liver/renal disease, diabetes, alcoholism, malignancy, asplenia):

• Combination therapy: Amoxicillin/clavulanate OR cephalosporin PLUS macrolide or doxycycline 1
• OR monotherapy: Respiratory fluoroquinolone (levofloxacin 750mg daily, moxifloxacin 400mg daily) 1

Inpatient Non-ICU Treatment:

Standard regimen: Beta-lactam (ceftriaxone or ampicillin/sulbactam) PLUS macrolide 1, 6

• Alternative: Respiratory fluoroquinolone monotherapy 6

ICU/Severe CAP Treatment:

Mandatory dual therapy: Third-generation cephalosporin PLUS either macrolide OR fluoroquinolone 6.

Special Pathogen Coverage:

Add MRSA coverage (vancomycin or linezolid) if:

• Prior MRSA respiratory isolation 1
• Recent hospitalization with IV antibiotics in last 90 days 1

Add Pseudomonas coverage (antipseudomonal beta-lactam plus aminoglycoside or fluoroquinolone) if:

• Prior Pseudomonas respiratory isolation 1
• Recent hospitalization with IV antibiotics in last 90 days 1

Critical Drug Interaction Check:

In elderly patients, those with polypharmacy, or multiple comorbidities, check for drug-drug interactions before prescribing fluoroquinolones or macrolides 4. This is a strong recommendation given the high risk of QT prolongation, tendon rupture, and other adverse effects in vulnerable populations.

---

Antibiotic Duration Protocol

For outpatients and hospitalized patients with non-severe CAP who achieve clinical stability: treat for 3-5 days (minimum 3 days), NOT the traditional 7-10 days 2, 3.

Duration Algorithm:

• Non-severe CAP with clinical stability: 3-5 days total 3
• Severe CAP requiring ICU: ≥5 days minimum 3

Clinical stability criteria (must meet ALL):

• Temperature ≤37.8°C
• Heart rate ≤100 bpm
• Respiratory rate ≤24/min
• Systolic BP ≥90 mmHg
• Oxygen saturation ≥90% on room air
• Able to take oral intake

---

Corticosteroid Use Decision Tree

Use corticosteroids ONLY in severe CAP requiring ICU admission—do NOT use in non-severe pneumonia 2, 3, 7.

Specific Protocol:

• Severe CAP: Consider corticosteroids (methylprednisolone or equivalent) within 36 hours of admission 6, 7
• Non-severe CAP: Do NOT use corticosteroids 3
• Influenza pneumonia: NEVER use corticosteroids 7

The evidence is conflicting 7, 5, with recent REMAP-CAP data suggesting benefit only in a very small subset. The safest approach: reserve for severe CAP with marked inflammatory syndrome, excluding influenza cases 7, 5.

---

Follow-up and Reassessment

Reassess response to therapy at 48-72 hours—failure to improve warrants investigation for complications (empyema, abscess), resistant organisms, or alternative diagnoses 1.

For patients with imaging abnormalities or risk factors for malignancy, obtain follow-up chest imaging at 6-12 weeks to ensure radiographic resolution 1.

Red Flags for Treatment Failure:

• Persistent fever beyond 72 hours
• Worsening respiratory status
• Hemodynamic instability
• New infiltrates on imaging